New drug cocktail aims to shrink breast tumors before surgery

NCT ID NCT07189884

Not yet recruiting Disease control Sponsor: The First Affiliated Hospital of Xiamen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase study is testing whether combining two targeted drugs (pyrotinib and dalpiciclib) with standard hormone therapy can shrink tumors in people with HR+HER2 low breast cancer before they have surgery. The study plans to enroll 33 patients with locally advanced disease. The main goal is to see how many patients have their tumors shrink or disappear completely after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pyrotinib and Dalpiciclib tablets combined with standard hormone therapy
What this could lead to: If successful, this could point toward a more effective pre-surgery treatment for HR+HER2 low breast cancer, potentially increasing the chance of eliminating all cancer cells before surgery.
What could go wrong: This is a very early, small study (33 people) with no control group, so results may not be conclusive. Side effects from the drug combination are possible and not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BREAST CANCER (LABC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED BREAST CANCER (LABC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.